



Cervical Dystonia

A Rare, Neurological Movement Disorder



CERVICAL DYSTONIA

[Also referred to as Spasmodic Torticollis]

Is a **painful and disabling chronic condition** in which the neck muscles contract involuntarily, causing **abnormal movements** and **awkward posture** of the head and neck.¹

Cervical dystonia affects women approximately

2X
as often as men.²

Cervical dystonia typically affects people between

40-60
years of age.²

There are an estimated

60,000
Americans who experience cervical dystonia.²

BOTULINUM TOXIN (BoNT) injections are first-line treatment.³

86% of diagnosed patients receive BoNT injections.⁴

Challenges with Current Treatments



4 WEEKS



8 WEEKS



10 WEEKS



Conventional BoNTs start to **WEAR OFF IN 8-10 WEEKS**⁴ and payers typically only allow retreatment every **12 WEEKS**.⁴



PATIENTS' PAINFUL SYMPTOMS OFTEN REAPPEAR BEFORE THEIR NEXT BoNT TREATMENT⁵

Duration of symptom relief from cervical dystonia is a **critically important factor** for both physicians and their patients.⁶



Burden for patients to travel to clinic for treatment every **3 months**.⁴

71%

of patients **desire longer lasting benefits** between treatments.⁵



CERVICAL DYSTONIA is a painful, often debilitating condition. A BoNT with **longer duration of effect** could result in less frequent reinjection and should thus be associated with decreased annualized drug cost, decreased health care utilization and overall treatment cost, as well as improved patient satisfaction.⁶

For more information contact Medical Affairs at medicalaffairs@revance.com



REFERENCES

1. Dystonia Medical Research Foundation. Web Site. <https://dystonia-foundation.org/what-is-dystonia/types-dystonia/cervical-dystonia/>. Accessed 8/11/20
2. NORD Web Site <https://rarediseases.org/rare-diseases/cervical-dystonia/>. Accessed 8/11/20
3. Simpson M et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology 2016
4. Revance® Market Research 2019: Understanding the Value of DaxibotulinumtoxinA for Injections' Therapeutic Franchise
5. Comella C, et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. Neurology, September 2020
6. Marsh W, et al. Systematic review and meta-analysis of the duration of clinical effect of on abotulinumtoxinA in cervical dystonia. BMC Neurology 2014